PDCD1 and cancer: Indeed, we observed both in vivo and in vitro that depletion of PMN-MDSCs using cabozantinib resulted in the sensitization of cancer cells to anti-PD-1/PD-L1 treatment that correlated with significant decreases in NOS2 and Arg1 and increased CTL proliferation and effector function.